APTO

Aptose Biosciences Inc

Add to Watchlist

Advanced Chart

2.110

+0.4(23.392%)1D

Overview
Forecast
Valuation
Earnings

High

2.110

Open

2.110

VWAP

Vol

Mkt Cap

13.58M

Low

2.110

Amount

EV/EBITDA(TTM)

Total Shares

18.11M

1.89M

EV/OCF(TTM)

P/S(TTM)

Aptose Biosciences Inc. is a clinical-stage biotechnology company engaged in developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

2 Analyst Rating

338.39% Upside

Wall Street analysts forecast APTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APTO is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

338.39% Upside

Current: 2.110

Low

6.00

Averages

9.25

High

12.50

338.39% Upside

Current: 2.110

Low

6.00

Averages

9.25

High

12.50

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$2 → $6

2025-03-28

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$2 → $6

2025-03-28

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-02-12

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-02-12

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-01-10

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-01-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-12-10

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-12-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-12-03

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-12-03

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$7 → $2

2024-11-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$7 → $2

2024-11-20

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aptose Biosciences Inc (APTO.O) is -0.34, compared to its 5-year average forward P/E of -3.95. For a more detailed relative valuation and DCF analysis to assess Aptose Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.95

Current PE

-0.34

Overvalued PE

2.94

Undervalued PE

-10.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.32

Current EV/EBITDA

-0.35

Overvalued EV/EBITDA

0.81

Undervalued EV/EBITDA

-3.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

25.69

Current PS

0.00

Overvalued PS

134.37

Undervalued PS

-82.99